Cross‐Ancestry Genome‐Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations

Author:

Khor Chiea Chuen123,Winter Stefan45,Sutiman Natalia6,Mürdter Thomas E.45,Chen Sylvia6ORCID,Lim Joanne Siok Liu6,Li Zheng1ORCID,Li Jingmei1ORCID,Sim Kar Seng1ORCID,Ganchev Boian45,Eccles Diana78,Eccles Bryony78,Tapper William78,Zgheib Nathalie K.9ORCID,Tfayli Arafat10,Ng Raymond Chee Hui11,Yap Yoon Sim11,Lim Elaine11,Wong Mabel11,Wong Nan Soon12,Ang Peter Cher Siang12,Dent Rebecca11,Tremmel Roman45ORCID,Klein Kathrin45,Schaeffeler Elke4513,Zhou Yitian14ORCID,Lauschke Volker M.4515ORCID,Eichelbaum Michel45,Schwab Matthias413161718ORCID,Brauch Hiltrud B.451318ORCID,Chowbay Balram3619ORCID,Schroth Werner45ORCID

Affiliation:

1. Division of Human Genetics Genome Institute of Singapore Singapore Singapore

2. Singapore Eye Research Institute Singapore Singapore

3. Clinical Pharmacology, SingHealth Singapore Singapore

4. Dr Margarete Fischer‐Bosch Institute of Clinical Pharmacology Stuttgart Germany

5. University Tübingen Tübingen Germany

6. Clinical Pharmacology Laboratory, Division of Cellular and Molecular Research National Cancer Centre Singapore Singapore

7. Faculty of Medicine, Cancer Sciences Academic Unit and University of Southampton Clinical Trials Unit University of Southampton Southampton UK

8. University Hospital Southampton National Health Service Foundation Trust Southampton UK

9. Department of Pharmacology and Toxicology, Faculty of Medicine American University of Beirut Beirut Lebanon

10. Hematology‐Oncology Division, Department of Internal Medicine, Faculty of Medicine American University of Beirut Beirut Lebanon

11. Division of Medical Oncology National Cancer Centre Singapore Singapore

12. OncoCare Cancer Centre, Mount Elizabeth Novena Medical Centre Singapore Singapore

13. Image‐Guided and Functionally Instructed Tumor Therapies Cluster of Excellence (iFIT) University of Tübingen Tübingen Germany

14. Department of Laboratory Medicine Karolinska Institute Stockholm Sweden

15. Department of Physiology and Pharmacology Karolinska Institute Stockholm Sweden

16. Department of Clinical Pharmacology University of Tübingen Tübingen Germany

17. Department of Biochemistry and Pharmacy University of Tübingen Tübingen Germany

18. German Cancer Consortium (DKTK), German Cancer Research Center, Partner Site Tübingen Tübingen Germany

19. Centre for Clinician‐Scientist Development Duke–National University of Singapore Medical School Singapore Singapore

Abstract

The therapeutic efficacy of tamoxifen is predominantly mediated by its active metabolites 4‐hydroxy‐tamoxifen and endoxifen, whose formation is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6). Yet, known CYP2D6 polymorphisms only partially determine metabolite concentrations in vivo. We performed the first cross‐ancestry genome‐wide association study with well‐characterized patients of European, Middle‐Eastern, and Asian descent (n = 497) to identify genetic factors impacting active and parent metabolite formation. Genome‐wide significant variants were functionally evaluated in an independent liver cohort (n = 149) and in silico. Metabolite prediction models were validated in two independent European breast cancer cohorts (n = 287, n = 189). Within a single 1‐megabase (Mb) region of chromosome 22q13 encompassing the CYP2D6 gene, 589 variants were significantly associated with tamoxifen metabolite concentrations, particularly endoxifen and metabolic ratio (MR) endoxifen/N‐desmethyltamoxifen (minimal P = 5.4E−35 and 2.5E−65, respectively). Previously suggested other loci were not confirmed. Functional analyses revealed 66% of associated, mostly intergenic variants to be significantly correlated with hepatic CYP2D6 activity or expression (ρ = 0.35 to −0.52), and six hotspot regions in the extended 22q13 locus impacting gene regulatory function. Machine learning models based on hotspot variants (n = 12) plus CYP2D6 activity score (AS) increased the explained variability (~ 9%) compared with AS alone, explaining up to 49% (median R2) and 72% of the variability in endoxifen and MR endoxifen/N‐desmethyltamoxifen, respectively. Our findings suggest that the extended CYP2D6 locus at 22q13 is the principal genetic determinant of endoxifen plasma concentration. Long‐distance haplotypes connecting CYP2D6 with adjacent regulatory sites and nongenetic factors may account for the unexplained portion of variability.

Funder

National Research Foundation Singapore

Robert Bosch Stiftung

Deutschen Konsortium für Translationale Krebsforschung

Deutsches Krebsforschungszentrum

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3